CJC-1295 with DAC

CJC-1295 with DAC is the Drug Affinity Complex version of Modified GRF (1-29), featuring a maleimido derivative of lysine at position 16 that forms a covalent bond with serum albumin after injection. This albumin conjugation dramatically extends the compound's plasma half-life from approximately 30 minutes (No DAC version) to 6-8 days, creating a sustained elevation of GHRH signaling rather than the pulsatile pattern produced by the No DAC variant. This makes CJC-1295 with DAC the longest-acting GHRH analog available to researchers.

The mechanism of action is identical to the No DAC version — GHRH receptor activation on pituitary somatotrophs — but the pharmacokinetic profile is fundamentally different. Rather than amplifying individual GH pulses, CJC-1295 with DAC creates a continuous GHRH stimulus that elevates both basal and pulsatile GH secretion over several days. Research has documented sustained GH elevations of 2-10 fold and IGF-1 increases of 40-100% lasting for up to 6-14 days following a single injection. This sustained profile means fewer injections but also means the GH elevation cannot be precisely timed around sleep or training the way No DAC can.

The research literature documents robust increases in lean body mass, reductions in fat mass, and improvements in recovery and sleep quality with CJC-1295 with DAC. The sustained GH/IGF-1 elevation profile makes it particularly relevant for researchers focused on long-term anabolic and anti-aging outcomes rather than acute peri-workout GH pulses. Some researchers prefer the convenience of twice-weekly or weekly injection schedules over the multiple daily injections required by the No DAC version.

CJC-1295 with DAC is suited for researchers who prioritize convenience and sustained GH elevation over precise pulse timing. Researchers should understand the trade-off: the DAC version produces higher total GH output per week but does not replicate the physiological pulsatile pattern as faithfully as the No DAC version. Some researchers alternate between the two or use DAC as a baseline with No DAC for acute pulse amplification.

Reconstitute with 2.5ml bacteriostatic water (yielding 2mg/ml). Administer via subcutaneous injection, typically 1-2mg per dose, once or twice weekly. The extended half-life means dosing frequency is low. Store at 2-8C after reconstitution. Lyophilized powder is stable at room temperature for weeks but should be refrigerated for extended storage. A single 5mg vial supports 2.5-5 weeks of research at standard dosing.